Ocular and Systemic Complications of COVID-19: Impact on Patients and Healthcare
Reads0
Chats0
TLDR
A mini-review summarizes the potential complications and treatments of the SARS-CoV-2 virus on the systemic and ocular health of patients, as well as the effects of delayed health care as discussed by the authors .Abstract:
There is increasing information available about the effects of the SARS-CoV-2 virus on the systemic and ocular health of patients, as well as the effects of delayed health care. This mini-review summarizes the potential complications and treatments of COVID-19. Systemic findings include respiratory illness, risk of thromboembolic events, and neurologic findings. Some patients may develop persistent symptoms even after the infection resolves. Effective treatment options include glucocorticoids, antivirals, interleukin-6 antagonists, monoclonal antibodies, Janus kinase inhibitors and vaccines. Potential ocular findings of COVID-19 include conjunctivitis, cranial nerve palsies, and microvascular changes in the retina; most symptoms resolved over time. During the lockdown periods, teleophthalmology was utilized to triage non-urgent issues; patients who did present to emergency departments tended to have more severe disease with worse visual prognoses. While transient delays in outpatient ophthalmic care may be tolerated in some patients, others experienced significant vision loss with interruptions in treatments. Resumption of ophthalmic care as soon as possible may help mitigate the effects of delayed care due to the pandemic. read more
Citations
More filters
Journal ArticleDOI
Ocular Complications after COVID-19 Vaccination, Vaccine Adverse Event Reporting System
TL;DR: A review of data suggests a possible association between COVID-19 vaccines and ocular adverse events, and Physicians are cautioned not only to be aware of this potential problem, but to check any underlying patient conditions, and to carefully document in VAERS within a few weeks of vaccination.
Journal ArticleDOI
Acute retinal necrosis in a patient on immunosuppressive treatment for COVID-19 pneumonia: a case report
TL;DR: In this article , a case of acute retinal necrosis (ARN) caused by Epstein-Barr Virus (EBV) that developed in a patient who had severe acute respiratory syndrome due to SARS-CoV-2 infection was reported.
Journal ArticleDOI
COVID-19 and ocular complications: A review of ocular manifestations, diagnostic tools, and prevention strategies
Jilian Dong,H. S. Chen,Yirui Zhu +2 more
TL;DR: A review of the ocular complications of COVID-19, the possible pathogenesis, and preventive strategies to protect ophthalmology practitioners and patients by reviewing the currently available literature on the topic is presented in this paper .
Journal ArticleDOI
Update on overview of ocular manifestations of COVID-19
M. Akbari,Maryam Dourandeesh +1 more
TL;DR: A narrative review on ocular manifestations during COVID-19 is presented, categorized into three main categories; ophthalmic, orbital, and neuro-ophthalmological manifestations with a detailed description of the presenting symptoms, risk factor, diagnostic, and therapeutic strategies suggested for each.
Journal ArticleDOI
Genome-Wide Pleiotropy Study Identifies Association of PDGFB with Age-Related Macular Degeneration and COVID-19 Infection Outcomes
Jaeyoon Chung,Viha Vig,Xinyu Sun,Xudong Han,George T. O'Connor,Xue-fang Chen,Margaret M. DeAngelis,Lindsay A. Farrer,Manju L Subramanian +8 more
TL;DR: In this paper , the authors evaluated the genetic architecture shared between AMD and COVID-19 (critical illness, hospitalization, and infections) using analyses of genetic correlations and pleiotropy.
References
More filters
Journal ArticleDOI
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
Behnood Bikdeli,Mahesh V. Madhavan,David Jiménez,Taylor Chuich,Isaac Dreyfus,Elissa Driggin,Caroline Der Nigoghossian,Walter Ageno,Mohammad Madjid,Yutao Guo,Liang V. Tang,Yu Hu,Jay Giri,Mary Cushman,Isabelle Quéré,Evangelos Dimakakos,C. Michael Gibson,C. Michael Gibson,Giuseppe Lippi,Emmanuel J. Favaloro,Jawed Fareed,Joseph A. Caprini,Alfonso Tafur,John R. Burton,Dominic P. Francese,Elizabeth Y. Wang,Anna Falanga,Claire McLintock,Beverley J. Hunt,Alex C. Spyropoulos,Geoffrey D. Barnes,John W. Eikelboom,John W. Eikelboom,Ido Weinberg,Sam Schulman,Marc Carrier,Gregory Piazza,Gregory Piazza,Joshua A. Beckman,P. Gabriel Steg,Gregg W. Stone,Stephan Rosenkranz,Samuel Z. Goldhaber,Samuel Z. Goldhaber,Sahil A. Parikh,Manuel Monreal,Harlan M. Krumholz,Stavros Konstantinides,Jeffrey I. Weitz,Gregory Y.H. Lip,Gregory Y.H. Lip +50 more
TL;DR: The current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexistingThrombotic disease who develop CO VID-19 are reviewed.
Journal ArticleDOI
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
Jamie Lopez Bernal,Nick Andrews,Charlotte Gower,Eileen Gallagher,Ruth Simmons,Simon Thelwall,Julia Stowe,Elise Tessier,Natalie Groves,Gavin Dabrera,Richard H. Myers,Colin Campbell,Gayatri Amirthalingam,Matt Edmunds,Maria Zambon,Kevin E. Brown,Susan Hopkins,Meera Chand,Mary Ramsay +18 more
TL;DR: The B.617.1.2 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Coronavirus disease 2019 (Covid-19), has contributed to the development of the disease.
Journal ArticleDOI
An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study.
Lucio Verdoni,Angelo Mazza,Annalisa Gervasoni,Laura Martelli,Maurizio Ruggeri,Matteo Ciuffreda,Ezio Bonanomi,Lorenzo D'Antiga +7 more
TL;DR: Children diagnosed after the SARS-CoV-2 epidemic began showed evidence of immune response to the virus, were older, had a higher rate of cardiac involvement, and features of MAS, and a similar outbreak of Kawasaki-like disease is expected in countries involved in the SEMS epidemic.
Journal ArticleDOI
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Denis Y. Logunov,Inna V. Dolzhikova,Dmitry V. Shcheblyakov,A. I. Tukhvatulin,Olga V. Zubkova,Alina S. Dzharullaeva,Anna V. Kovyrshina,Nadezhda L. Lubenets,Daria M. Grousova,Alina S. Erokhova,Andrei G. Botikov,Fatima M. Izhaeva,Olga Popova,Tatiana A Ozharovskaya,Ilias B Esmagambetov,Irina A Favorskaya,Denis I. Zrelkin,Daria V Voronina,Dmitry N. Shcherbinin,Alexander S. Semikhin,Yana V. Simakova,Elizaveta A. Tokarskaya,Daria A. Egorova,M M Shmarov,Natalia A. Nikitenko,Vladimir A. Gushchin,Elena A Smolyarchuk,Sergey Zyryanov,Sergei V. Borisevich,Boris S. Naroditsky,Alexander L. Gintsburg +30 more
TL;DR: Gam-COVID-Vac (Sputnik V) showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials as discussed by the authors.
Journal ArticleDOI
Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment-Elevation Myocardial Infarction Care in Hong Kong, China.
Chor Cheung Tam,Kent Shek Cheung,Simon S. K. Lam,Anthony Wong,Arthur Yung,Michael Sze,Yui Ming Lam,CW Chan,Tat Chi Tsang,Matthew Sh Tsui,Hung-Fat Tse,Chung-Wah Siu +11 more
TL;DR: The impact of the COVID-19 outbreak on STEMI care in Hong Kong is described through a handful of recent cases of patients with STEMI who underwent PPCI at a single center.